vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Cue Biopharma, Inc. (CUE). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $21.9M, roughly 1.6× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -1.8%, a 9.0% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs -3.2%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -3.5%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
CLFD vs CUE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $21.9M |
| Net Profit | $-614.0K | $1.6M |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | 9.0% |
| Net Margin | -1.8% | 7.2% |
| Revenue YoY | -3.2% | 1292.3% |
| Net Profit YoY | 67.8% | 116.7% |
| EPS (diluted) | $-0.04 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $21.9M | ||
| Q3 25 | $23.4M | $2.1M | ||
| Q2 25 | $49.9M | $3.0M | ||
| Q1 25 | $47.2M | $421.0K | ||
| Q4 24 | $29.7M | $1.6M | ||
| Q3 24 | $5.6M | $3.3M | ||
| Q2 24 | $48.8M | $2.7M | ||
| Q1 24 | $36.9M | $1.7M |
| Q4 25 | $-614.0K | $1.6M | ||
| Q3 25 | $-9.1M | $-7.4M | ||
| Q2 25 | $1.6M | $-8.5M | ||
| Q1 25 | $1.3M | $-12.3M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $-8.7M | ||
| Q2 24 | $-447.0K | $-10.2M | ||
| Q1 24 | $-5.9M | $-12.3M |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | 9.0% | ||
| Q3 25 | 10.3% | -353.4% | ||
| Q2 25 | 3.0% | -292.3% | ||
| Q1 25 | 0.6% | -2921.4% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | — | -264.2% | ||
| Q2 24 | -4.7% | -390.6% | ||
| Q1 24 | -26.4% | -737.8% |
| Q4 25 | -1.8% | 7.2% | ||
| Q3 25 | -38.8% | -346.6% | ||
| Q2 25 | 3.2% | -287.1% | ||
| Q1 25 | 2.8% | -2911.4% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | -259.6% | ||
| Q2 24 | -0.9% | -382.7% | ||
| Q1 24 | -16.0% | -719.1% |
| Q4 25 | $-0.04 | $0.05 | ||
| Q3 25 | $-0.65 | $-0.07 | ||
| Q2 25 | $0.11 | $-0.09 | ||
| Q1 25 | $0.09 | $-0.17 | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | $-0.17 | ||
| Q2 24 | $-0.04 | $-0.20 | ||
| Q1 24 | $-0.40 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $27.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $249.7M | $26.4M |
| Total Assets | $268.1M | $42.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $27.1M | ||
| Q3 25 | $106.0M | $11.7M | ||
| Q2 25 | $117.2M | $27.5M | ||
| Q1 25 | $112.0M | $13.1M | ||
| Q4 24 | $113.0M | $22.5M | ||
| Q3 24 | $129.0M | $32.4M | ||
| Q2 24 | $123.8M | $30.0M | ||
| Q1 24 | $142.9M | $41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | $1.0M | ||
| Q2 24 | $2.1M | $2.0M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $249.7M | $26.4M | ||
| Q3 25 | $256.2M | $13.2M | ||
| Q2 25 | $264.5M | $18.2M | ||
| Q1 25 | $265.9M | $6.6M | ||
| Q4 24 | $267.4M | $17.5M | ||
| Q3 24 | $275.8M | $25.4M | ||
| Q2 24 | $274.6M | $21.6M | ||
| Q1 24 | $279.2M | $30.0M |
| Q4 25 | $268.1M | $42.2M | ||
| Q3 25 | $306.2M | $31.6M | ||
| Q2 25 | $314.7M | $40.7M | ||
| Q1 25 | $310.9M | $22.3M | ||
| Q4 24 | $303.2M | $32.2M | ||
| Q3 24 | $315.3M | $44.8M | ||
| Q2 24 | $318.1M | $42.3M | ||
| Q1 24 | $315.4M | $54.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | 0.04× | ||
| Q2 24 | 0.01× | 0.09× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-1.1M |
| Free Cash FlowOCF − Capex | $-2.4M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 2.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $-1.1M | ||
| Q3 25 | — | $-9.0M | ||
| Q2 25 | $7.9M | $-3.4M | ||
| Q1 25 | $3.0M | $-8.2M | ||
| Q4 24 | $7.2M | $-36.3M | ||
| Q3 24 | $22.2M | $-7.5M | ||
| Q2 24 | $4.0M | $-10.0M | ||
| Q1 24 | $-5.7M | $-9.8M |
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | $-3.4M | ||
| Q1 25 | $654.0K | $-8.3M | ||
| Q4 24 | $5.1M | $-36.4M | ||
| Q3 24 | $18.2M | $-7.5M | ||
| Q2 24 | $2.8M | $-10.0M | ||
| Q1 24 | $-7.7M | $-9.8M |
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | -116.5% | ||
| Q1 25 | 1.4% | -1976.7% | ||
| Q4 24 | 17.1% | -2309.3% | ||
| Q3 24 | 323.0% | -225.7% | ||
| Q2 24 | 5.8% | -376.2% | ||
| Q1 24 | -20.8% | -573.0% |
| Q4 25 | 2.9% | 0.0% | ||
| Q3 25 | 2.0% | 0.0% | ||
| Q2 25 | 0.8% | 0.9% | ||
| Q1 25 | 5.1% | 35.6% | ||
| Q4 24 | 7.0% | 4.2% | ||
| Q3 24 | 71.4% | 0.0% | ||
| Q2 24 | 2.5% | 0.4% | ||
| Q1 24 | 5.3% | 3.2% |
| Q4 25 | — | -0.68× | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
